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ABSTRACT: Phase-sensitive in situ forming implants (ISFI) are a promising platform for the controlled release of therapeutic agents.
The simple manufacturing, ease of placement, and diverse payload capacity make these implants an appealing delivery system for a
wide range of applications. Tailoring the release profile is paramount for effective treatment of disease. In this study, three innovative
formulation modifications were used to control drug release. Specifically, water, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
perchlorate (DiI), and bovine serum albumin (BSA) were incorporated into an ISFI solution containing the small molecular weight mock
drug, sodium fluorescein. The effects of these additives on drug release, swelling, phase inversion, erosion, and implant microstructure
were evaluated. Diagnostic ultrasound was used to monitor changes in swelling and phase inversion over time noninvasively. Water, DiI,
and the combination of BSA/DiI functioned to reduce burst release 47.6%, 76.6%, and 59.0%, respectively. Incorporation of water into the
casting solution also enhanced the release of drug during the diffusion period of release by 165.2% relative to the excipient free control.
Incorporation of BSA into the polymer solution did not significantly alter the burst release (p < 0.05); however, the onset of degradation
facilitated release was delayed relative to the excipient-free control by 5 days. This study demonstrates that the use of excipients provides
a facile method to tailor the release profile and degradation rate of implants without changing the polymer or solvent used in the implant
formulation, providing fine control of drug dissolution during distinct phases of release. C© 2015 Wiley Periodicals, Inc. and the American
Pharmacists Association J Pharm Sci 104:3471–3480, 2015
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INTRODUCTION
Phase-sensitive in situ forming systems have been used for fab-
rication of numerous products ranging from asymmetric mem-
branes for reverse osmosis filtration to drug eluting polymer
depots for the treatment of prostate cancer.1–7 These phase-
sensitive systems exist as liquid polymer solutions until in-
troduced to a nonsolvent, such as water, where the polymer
precipitates into a solid matrix through a process of phase
inversion.5,8–11 In medical applications, phase-sensitive in situ
forming implants (ISFI) are of interest because they provide
a platform by which drug can be delivered through a mini-
mally invasive injection, which facilitates accurate placement
of the implant in a desired location for the controlled local de-
livery of drug over time.12 These implants are manufactured
by dissolving a biodegradable polymer into a biocompatible sol-
vent, which can be mixed with a drug to form a suspension
or solution.13,14 During phase inversion, the nonsolvent dif-
fuses into the polymer solution, whereas the solvent diffuses
out of the implant into the surrounding environment result-
ing in an unstable ternary system until sufficient nonsolvent
can induce precipitation of the polymer.5,6 A number of systems
have been used to characterize the phase inversion process such
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as dark ground imaging, electron spin resonance, and ultra-
sound imaging.10,15–18 Ultrasound imaging works by detecting
the changes in acoustic impedance that occur as the polymer
precipitates out of solution.6,17 It is the only method that allows
for the visualization of the process both in vitro and in vivo, and
can be used to detect other processes such as implant swelling
and erosion.14,19
Phase-sensitive ISFIs have a release profile with three dis-
tinct phases.20 Burst release occurs over the course of the first
24–48 h and is identified as the initial rapid release of drug
from the implant. Diffusion-facilitated release occurs as the
drugmoves through the polymermatrix and is controlled by the
implantmicrostructure.21–23 Degradation-facilitated release oc-
curs as a result of polymer degradation increasing the intercon-
nectivity of the porous microstructure of the implant and re-
sults in an increase in the release of drug. A number of methods
have been used to control the release profile of phase-sensitive
ISFIs, typically by altering the mass transfer kinetics of the
solvent/nonsolvent in order to increase or decrease the porosity
of the polymer matrix.8,21,23–25 Factors such as changes in the
polymer molecular weight (MW), concentration of the casting
solution, or the solvent composition have all been successfully
used to change the release profile of the implant.16,19,22,26–30
However, these changes often result in an increased solution
viscosity that can limit the injectability of the solution.31 The
use of additives provides a means to alter distinct phases of the
release profile of phase-sensitive ISFIs, and tailor the release
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profile for a specific application, without increasing the solution
viscosity.
In the present study, the effect of three unconventional
additives on the release profile from ISFIs was evaluated.
These excipients function as agents added to the polymer for-
mulation solution to enhance the function of the implants,
without inducing a therapeutic effect.32 Water was incor-
porated into the casting solution in order to change the
solvent/nonsolvent mass transfer kinetics. 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) has
been shown to increase the hydrophobicity of the polymer solu-
tion and consequently reduce the interconnectivity of the inter-
nal porous network,14 andwas selected to reduce both burst and
diffusion-facilitated release. Bovine serum albumin (BSA) has
been shown to reduce the erosion of ISFIs, and was introduced
to alter the onset of degradation-facilitated release.14 Finally, a
combination of BSA/DiI was used to evaluate the combinatorial
effect of additives on the release profile. Changes in drug release
were evaluated by measuring the dissolution kinetics of the
mock drug sodium fluorescein (MW = 376, log P = −1.52, pKa
= 6.4).14,33 Sodium fluorescein was specifically chosen because
it is a small molecular weight hydrophilic agent that has a re-
lease profile with distinct regions of release following a pattern
of burst, diffusion, and degradation-facilitated release. Further-
more, this mock drug also has a release profile similar to that
observed with the therapeutic agent doxorubicin.14 Implant
erosion and fluid uptake were measured by monitoring changes
in the implant mass. Polymer phase inversion was evaluated
using ultrasound imaging, and the implant microstructure was
evaluated using scanning electron microscopy (SEM). Results
from this study will provide insight into additional methods for
controlling the release profile of ISFIs, providing control over
the dissolution and degradation kinetics of drugs during each
distinct phase of release.
MATERIALS AND METHODS
Materials
Poly(DL-lactic-co-glycolic acid) (PLGA; 50:50, MW 21,000 Da)
was obtained from Evonik Industries (Rellinghauser Strasse,
Germany) and used as received. N-methyl-2-pyrrolidinone
(NMP), sodiumfluorescein, andBSAwere used as received from
Sigma–Aldrich (St. Louis, Missouri). DiI was used as received
from Advancing Assay and Test Technologies (Sunnyvale,
California). Agarose and phosphate-buffered saline (PBS) were
received from Fischer Scientific (Waltham, Massachusetts).
Polymer Solution Formulations
Control solutions with no additives were prepared using a
39:60:1 mass ratio of PLGA–NMP–fluorescein by first sus-
pending or dissolving the fluorescein in NMP as previously
described.14,19 One hour before injection into the bath solu-
tion, BSA was added to the caste solution (35:60:4:1 mass ra-
tio of PLGA:NMP:BSA:fluorescein), and allowed to mix using
a magnetic stirrer. The solutions were then warmed to 37°C
in order to eliminate air bubbles in the solution. Solutions con-
tainingDiI (35:60:4:1mass ratio of PLGA:NMP:DiI:fluorescein)
were prepared by first dissolving the fluorescein and DiI in
NMP, followed by addition of the PLGA, which was stirred
overnight in a 37°C shaker table at 90 rpm. Solutions
containing both DiI and BSA (BSA/DiI) (35:60:2:2:1 mass
ratio of PLGA:NMP:BSA:DiI:fluorescein) were prepared by
first dissolving the fluorescein and DiI in NMP, then adding
PLGA and stirred overnight, with BSA added as described
earlier. Solutions containing water (39:54:6:1 mass ratio of
PLGA:NMP:water:fluorescein) were prepared similar to control
solutions, but a 10% water in NMP solution was used instead
of pure NMP. Polymer solutions with water were prepared the
day before use; all other formulations were stored at 4°C and
used within 3 days.
Cumulative Drug Release
Drug release profiles were evaluated as described previously.14
First, polymer solution (42.9 ± 5.2 mg) was injected into 10 mL
of 37°C PBS (pH 7.4), and then placed in an incubated orbital
shaker (37°C at 90 rpm). Over the course of the first 6 h, 1 mL
of solution was sampled and then replaced with 1 mL of fresh
warm PBS at predetermined time points (0, 0.5, 1, 2, 4, and 6 h
after injection into PBS). After 24 h, a sample was taken, and
then the bath solution was completely removed and replaced by
10 mL of fresh buffer daily for 14 days. After 14 days, implants
were removed from the bath solution and degraded in 5 mL of
2MNaOH. Fluorescein mass was determined bymeasuring the
fluorescence in the solution samples that was compared with
a standard curve of known fluorescein concentrations using a
multimode microplate reader (Infinite 200 series; Tecan Ltd.;
Ma¨nnedorf, Zu¨rich, Switzerland) at excitation/emission wave-
lengths of 485/525 nm. Cumulative drug release was calculated
from these measurements and normalized by the total mass of
drug in the implant.
Implant Imaging
Implants were imaged using diagnostic ultrasound as previ-
ously described.17 Briefly, implants were imaged through the
Z-axis by immobilizing a 12-MHz transducer (Aplio XG; Toshiba
Medical Systems;Minato, Tokyo, Japan) below an agarosemold
containing the implant. Images were taken at predetermined
time points over the course of the first 24 h (0, 0.5, 1, 2, 4, 6,
and 24 h after the implants were added to PBS), and then im-
aged daily until the study was terminated. The buffer solution
was replaced daily after the images were taken. Implants were
maintained at 37°C at 90 rpm for the duration of the study. Im-
age analysis was performed to monitor changes in the polymer
shell thickness by using a custom MatLab code as previously
described (MathWorks Inc., Natick, Massachusetts).17,34 First,
a threshold was applied to the image in order to create a bi-
nary mask, which was normalized by the sum of the total num-
ber of pixels within the cross-sectional area of the implant.17,34
Changes in the implant cross-sectional area over time were
used as a metric of the implant swelling.17,34
Erosion and Bathside Uptake
Changes in implant mass with respect to time were monitored
as describe previously.14,19 First, the initial mass of implants
added to 10 mL of warm PBS (pH 7.4) was recorded and then
kept in an incubated shaker (37°C at 90 rpm). Then, implants
were removed from the bath solution at predefined time points
(1, 3, 7, 10, 14, 17, and 21 days after the polymer solution was
added to PBS). At each time point, implants were dried with a
clean paper towel, and then weighed in order to obtain the wet
mass. The implants were then frozen, followed by lyophiliza-
tion for 4 days. After lyophilization, the implant dry mass was
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Figure 1. Cumulative release of sodium fluorescein over the course of 14 days (a) and 28 days (b). All error bars represent standard deviation
with n = 3.
recorded. Fluid uptake was calculated by subtracting the wet
mass from the initial mass then normalizing by the initial im-
plant mass. Polymer erosion was determined by normalizing
the implant dry mass with the theoretical polymer mass of the
implant. Sink conditions were maintained by replacing the to-
tal volume of the buffer solution daily.
Scanning Electron Microscope Imaging and Analysis
Implant microstructure was evaluated as previously
described.14 Briefly, the implants were frozen and then
fractured over dry ice. After the implants were freeze-
fractured, the samples were lyophilized for 4 days. Next, the
implants were mounted on an aluminum stub using carbon
tape, and sputter coated with 5 nm of Pd. The coated samples
were then imaged using a Quanta 200 3D ESEM (Hillsboro,
OR) with an acceleration voltage of 3.5 kV and a hole size
of 10.
Statistical Analysis
Statistical significance was performed using Minitab (Minitab
Inc., State College, Pennsylvania). One-way analysis of vari-
ance (ANOVA, p < 0.05) was used to determine statistical
significance, and a Tukey multicomparison test was used to
compare differences between groups. All data were reported as
mean ± standard deviation.
RESULTS
Cumulative Drug Release
In situ forming implants have characteristic release kinetics
consisting of three distinct phases of release: burst, diffusion,
and degradation. Burst release occurred over the course of the
first 24 h after injection into the bathside solution. No signifi-
cant difference in burst release was observed between implants
formulated without additives and those containing BSA (28.8±
3.0% and 32.9± 3.2%); however, these implant formulations did
have a significantly greater burst release than all other depot
formulations (Fig. 1). The additives water, DiI, and BSA/DiI
reduced the average burst release by 47.6%, 75.9%, and 58.8%,
respectively.
Table 1. Average Release of Mock Drug at Each Phase of Release
Burst Diffusion Degradation
(%) (%/day) (%/day)
Excipient free 28.8 ± 3.0 2.3 ± 0.2 4.5 ± 1.7
Water 15.1 ± 0.3 6.1 ± 0.1 –
DiI 6.9 ± 0.8 1.5 ± 0.3 6.5 ± 1.0
BSA 32.9 ± 3.2 1.3 ± 0.1 4.4 ± 0.3
BSA–DiI 11.8 ± 1.3 1.0 ± 0.1 2.0 ± 0.3
The diffusion period of release occurred after 24 h, and
the onset of degradation-facilitated release was determined by
evaluating the derivative of the release plots.19 Implants that
used water as an additive had a significantly greater release
rate than all other implant formulations (6.1 ± 0.1%/day). The
addition of BSA or DiI into the polymer solution significantly
reduced the daily release rate of mock drug from the implants
(1.3 ± 0.1%/day and 1.5 ± 0.3%/day for BSA and DiI, respec-
tively) compared with implants that contained no additives
(2.3 ± 0.2%/day). The greatest decrease in diffusion-facilitated
release was observed using a combination of BSA/DiI in the
depot, resulting in a release rate of 1.0 ± 0.1%/day.
Degradation-facilitated release was not observed when wa-
ter was used as the additive (Fig. 1). However, a significant
increase in the drug dissolution rate was observed for all other
implant formulations. The use of DiI and BSA/DiI did not al-
ter the onset of degradation-facilitated release, but incorpora-
tion of BSA alone delayed degradation facilitated release for
5 days. The use of BSA or DiI as standalone additives did not
significantly alter the daily dissolution kinetics of mock drug
during degradation-facilitated release. However, significantly
lower dissolution kinetics was observed from implants that con-
tained the combination of BSA/DiI. The release rate results are
summarized in Table 1.
Ultrasound Characterization
Implant Morphology
Representative gray-scale images of the implant cross-section
over time are shown in Figure 2. Implants without an addi-
tive developed a thin shell immediately after injection into the
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Figure 2. Representative ultrasound images of the same implant over the course of the study. Polymer precipitation results in white, whereas
darker areas suggest a polymer lean domain. Row 1 is an excipient-free control, row 2 contains water in the casting solution, row 3 contains DiI,
row 4 contains BSA, and row 5 is a combination of BSA/DiI.
Figure 3. Comparison of implant morphology obtained using SEM with those obtained from ultrasound.
bathside. Over time, an increase in hyperechoic regions were
observed as the polymer precipitated. After 6 days in the non-
solvent, large pores began to form in the center of the implant,
which increased in diameter over the duration of the study.
When water was used as the additive, implant behavior fol-
lowed a similar pattern of formation. However, the development
of the central pore did not occur until after 9 days in the bath-
side, and the pore diameter did not expand (Fig. 2). Implants
formulated with DiI precipitated more rapidly than those with-
out additives; additionally, the formation of the central pore
occurred after 5 days followed by the implant collapsing after
9 days (Fig. 2). Implants that contained BSA had a high initial
echogenic signal. This elevated echogenicity was lost within the
first half hour, followed by the gradual increase in backscatter
over the course of the first 24 h. Development of an interior pore
did not occur until after 9 days in the nonsolvent, and the pore
did not expand during the study. Implants with the combina-
tion of BSA/DiI had an initial elevated echogenic signal similar
to implants with BSA alone, but the central pore did not oc-
cur until after 10 days. Image validation was performed by
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Figure 4. Quantitative formation data of ISFIs (a) and the change in
the implant cross-sectional area over time (b). All error bars represent
standard deviation with n = 3.
comparing the ultrasound images to SEM images of cryo-
sectioned implants, demonstrating that pore formation ob-
served using ultrasound imaging could be observed in the im-
plants for all polymer solution formulations (Fig. 3).
Phase Inversion
Initial polymer precipitation occurred rapidly, reaching 69.1 ±
7.3% after 1 day for implants with no additives. These implants
then continued to phase invert more slowly, with a peak poly-
mer precipitation occurring after 4 days lasting through 6 days.
After 6 days, a loss of signal was observed because of the for-
mation of the central pore, which resulted in a decrease in the
precipitated area. When water was used as the excipient, peak
polymer precipitation occurred after 4 days, with no significant
loss in signal occurring throughout the remainder of the study
(Fig. 4a). Implants containing DiI rapidly precipitated over the
course of the first 2 h, with no significant changes occurring
until after 6 h, where more gradual precipitation occurred un-
til reaching a peak after 2 days. After 5 days, a loss of signal
was observed as a result of the formation of the pore. Implants
with BSA and BSA/DiI both reached a maximum polymer
precipitation after 1 day. A reduction in backscatter occurred
after 1 day, but was not the result of a pore.
Implant Swelling
Implants without excipient initially shrink, and returned to
the initial cross-sectional area after 4 h. The implants then
continued to swell, reaching a maximum of 1.64-fold the ini-
tial cross-sectional area after 6 days (Fig. 4b). Implants using
water as the excipient followed a similar pattern of swelling.
Peak swelling occurred after 6 days, and reached a maximum
of 1.69 ± 0.04-fold more than the initial cross-sectional area.
Implants that contained DiI initially shrink and then reached
a maximum cross-sectional area after 2 days in PBS (1.22 ±
0.03-fold the initial area); however, no significant changes in
cross-sectional area occurred after 24 h (Fig. 4b). BSA-loaded
implants did not undergo an initial loss in area, increasing to
1.74± 0.11-fold the initial cross-sectional area after 1 day, with
no significant changes occurring throughout the remainder of
the study. Implants that contained the combination of BSA/DiI
initially shrink, returning to the initial area after 4 h. The
implants then continued to swell through 4 days, and achieved
a maximum area of 1.41 ± 0.06-fold the initial cross-sectional
area, with no significant changes occurring through the remain-
der of the study.
Erosion and Bathside Uptake
Initially, all implant formulations had masses greater than the
maximum theoretical polymer mass, indicating the presence
of residual solvent (Fig. 5a). Implants without excipients and
implants incorporating water as the additive had significantly
lower masses than all other implant formulations after 7 days
(99.1 ± 5.1% and 94.5 ± 1.8% of the initial polymer mass, re-
spectively), and were below the theoretical polymer mass, in-
dicating the onset of erosion. Within 10 days, implants that
incorporated water as the excipient had a significantly lower
mass than all other implant formulations. Implants with DiI,
BSA, and BSA/DiI still contained residual solvent on day 10
(104.1 ± 2.1%, 101.9 ± 0.7%, and 104.8 ± 0.8% of the theo-
retical polymer mass, respectively), but by 14 days all implant
formulations had begun eroding. No statistical differences were
observed in the erosion profile of implants containing DiI, BSA,
or BSA/DiI (Fig. 5a).
Significant differences in fluid uptake occurred between all
groups after 3 days in solution and these differences weremain-
tained until after 10 days in the bathside solution (Fig. 5b).
The excipient-free control demonstrated the greatest fluid up-
take, followed by implants containing water, then those with
BSA, which was followed by those with BSA/DiI, and finally
implants with DiI alone. Implants without an excipient had a
4.1 ± 0.1-fold increase in the initial implant mass after 7 days
in PBS. The initial 7-day period of fluid uptake was followed
by a decrease in the wet mass of the implants over the remain-
der of the study (Fig. 5b). The implant with water incorporated
into the casting solution followed a similar pattern, but had
a significantly lower fluid uptake than the excipient free con-
trol, reaching a maximum 3.1 ± 0.1-fold increase in implant
mass after 7 days. Implants containing BSA rapidly reached
a steady state, and were 2.4 ± 0.01-fold the initial implant
mass after 24 h in the nonsolvent, with no significant changes
in the wet mass of the implants occurring until after 14 days
(Fig. 5b). After 14 days, a decrease in thewetmasswas observed
throughout the remainder of the study. Implants that contained
a combination of BSA/DiI had a 1.9± 0.03-fold increase inmass
after 1 day in the bathside solution, and no significant changes
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Figure 5. Implant erosion over time (a) and the change in fluid uptake
over time (b). All error bars represent standard deviation with n = 3.
occurred in the implant mass afterward. Implants that con-
tained DiI had an initial period of fluid uptake resulting in a
1.8 ± 0.3-fold increase in the implant mass, with no significant
changes observed until after 17 days in the bathside solution.
On the final day of the study, a significant decrease in the im-
plant mass was observed, resulting in an implant with a wet
mass 0.7 ± 0.1-fold the initial mass of the implant.
Implant Microstructure Analysis
Within 3 days, the microstructure of implants without an ex-
cipient had a shell and an interior spongy domain, with a cen-
tral region that still had residual solvent (Fig. 6). This interior
spongy domain consisted of a small interconnected porous net-
work, of polymer-rich and polymer-lean domains. The incorpo-
ration of water into the casting solution resulted in a decrease
in the implant shell thickness, and resulted in the formation
of a continuous porous network throughout the implant struc-
ture, including the shell. Incorporation of DiI into the polymer
solution resulted in an implant with a thinner shell than the
excipient-free control, but with larger less interconnected pores
in the interior of the implant. Incorporation of BSA resulted in
a thick outer shell similar to what is observed in the excipient-
free control. The interior domain had smaller pores than what
was observedwhenDiI was included in the casting solution, but
the pores were less interconnected than the excipient-free con-
trol. The combination of BSA/DiI resulted in an implant with
a microstructure similar to what was observed with implants
containing BSA alone. The implants containing BSA/DiI also
had a few larger pores in the interior domain of the implants
similar to what was observed with implants containing only DiI
(Fig. 6).
After 7 days, the shell of the excipient-free control became
thinner and the interior domain becamemore porous and inter-
connected (Fig. 7). Themicrostructure of implants that incorpo-
rated water into the casting solution had a less dense shell and
interior domain, with greater interconnectivity of the porous in-
terior domain. Implants containing DiI developed larger pores
just beginning to become interconnected (Fig. 7). Although the
shell remained dense, polymer-lean domains were also begin-
ning to form. Implants that contained BSA did not significantly
change between day 3 and day 7. The microstructure of im-
plants with the combination of BSA/DiI appeared more dense,
with a less interconnected porous network than the excipient-
free control, and an increase in the size of the polymer-lean
domains (Fig. 7).
DISCUSSION
Additives provide a means by which the drug release profile
of ISFIs can be specifically tailored at unique phases of the
release profile, without making changes to the polymer or the
solvent, which can have adverse affects on the solution vis-
cosity. The effect that the additive has on drug release is de-
pendent on the way in which the excipient interacts with the
surrounding matrix, payload, or how it alters the mass transfer
kinetics of the solvent/nonsolvent.5,8,35 For highly miscible sol-
vents, the polymer precipitates instantaneously resulting in a
dense polymer shell.5 Within the implant interior, polymer-lean
droplets consisting of a mixture of solvent and nonsolvent form.
These droplets will aggregate into larger domains unless a suf-
ficient concentration of nonsolvent is present, which stabilizes
the structure by causing the polymer to precipitate.5,6 This pro-
cess results in the formation of a highly interconnected porous
network, observed in the implants without excipients. The in-
terconnectivity of the pores was hypothesized by McHugh and
coworkers9,21–23 to provide a network for drug diffusion ulti-
mately leading to elevated burst release, which occurs as drug
is depleted from these polymer-lean regions. As a consequence
of the structure, diffusion is limited resulting in the character-
istic release profile.
We hypothesized that the incorporation of DiI into the poly-
mer solution would function to increase the hydrophobicity of
the polymer solution and reduce water uptake. The increased
hydrophobicity and decrease in water uptake resulted in de-
layed demixing to occur after the initial shell formation. As
a consequence of the delayed demixing, the polymer-lean do-
mains could not be stabilized by the nonsolvent and aggre-
gated, resulting in the observed microstructure that consisted
of large pores with little interconnectivity (Fig. 6). The limited
interconnectivity of the pores reduced burst release and limited
diffusion of drug through the implant.
Incorporation of nonsolvent into the casting solution has
been used to control themicrostructure of asymmetric and sym-
metric membranes fabricated using phase inversion.1,5,10,11,18,35
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Figure 6. Scanning electron microscopy images of implants in the bath solution after 3 days. Each row is representative of implants loaded
with different excipients. Column 1 is a low magnification image of the entire implant, column 2 is an image of the shell, and column 3 is an
image of the center of the implant.
Therefore, water was added to the casting solution in order to
reduce the solvent/nonsolvent gradient. As a consequence of the
reduced solvent exchange, lower fluid uptake was observed, as
well as a decrease in burst release that we hypothesize to be a
result of a decrease in solvent transport. SEM analysis of the
microstructure shows that incorporating water into the poly-
mer solution also reduced the shell thickness of the implants,
which we hypothesize resulted in the enhanced release of drug
during the diffusion phase of release.
Through ultrasound imaging, all of the implants were ob-
served to become hollow if given a large enough timescale
(Figs. 1 and 3). A similar observation has been described
in previous studies.14,19,28,36 We hypothesize that the develop-
ment of this macroscale feature occurs as a result of auto-
catalytic degradation and can be explained with percolation
theory.19,37–39 Because of the removal of the acidic degradation
biproducts from the surface of the implant by the nonsolvent,
and diffusion limitations of the acidic biproducts imparted by
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Figure 7. Scanning electron microscopy images of implants in the bath solution after 7 days. Each row is representative of implants loaded
with different excipients. Column 1 is a low magnification image of the entire implant, column 2 is an image of the shell, and column 3 is an
image of the center of the implant.
the shell, a pH gradient develops within the implant.19,37,40–42
The buildup of acidic biproducts continues until the matrix
that makes up the shell erodes below the percolation threshold,
resulting in a continuous path through which the oligomers can
diffuse out of the implant, and consequently causes the forma-
tion of a pore in the center of the implant.19 Recent studies by
Scha¨dlich et al.43 have demonstrated that the internal pH of an
ISFI decreases below 3 within the first 6 days in the bathside
solution, and is followed by an increase in pH, indicating loss
of the acidic biproducts.
We also hypothesize that the increased diffusion of the im-
plants that contained water in the casting solution reduced
the buildup of degradation biproducts and resulted in the pro-
longed formation of the central pore relative to the excipient-
free control. In previous studies, DiI was shown to enhance
the degradation of ISFIs.14 Therefore, we postulate that the
reduced interconnectivity, dense polymer regions, and elevated
hydrophobicity within the implants containing DiI result in a
greater decrease in pH within the macropores enhancing the
autocatalysis effect. Incorporation of BSA into ISFIs has been
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shown to reduce polymer erosion and degradation, and was
not anticipated to alter burst release.14 BSA is not soluble in
the polymer solution, and was suspended before injection into
the bathside solution. The BSA suspension provided points
of acoustic impedance mismatch within the polymer solution
resulting in an initial elevated backscatter. This increase in
echogenicity was lost within a half hour because of diffusion
of water into the polymer solution. Interestingly, a decrease
in signal was observed after 48 h, which we hypothesize to be
a result of increased polymer density attenuating the ultra-
sound signal transmitted through the implant. SEM images
showed that the implants had a denser, less interconnected
porous microstructure than the excipient-free control, which
we hypothesize functioned to reduce drug release during the
diffusion period of release. Furthermore, because of the isoelec-
tric point of the BSA, the pH gradient that develops in the
implant would serve to facilitate polyionic complexation of the
degraded oligomers that function to maintain the matrix ar-
chitecture ultimately reducing polymer erosion and delaying
the onset of degradation-facilitated release. The reduction in
release may also be effected by interaction of fluorescein with
BSA, which would also serve to reduce release during the dif-
fusion and degradation phases of drug dissolution.
When a combination of DiI/BSA was incorporated into the
casting solution, synergistic effects of both excipients were ob-
served. A dense polymer shell was formed similar to what was
observed with implants containing BSA alone (Fig. 6). Because
of the reduced fluid uptake, a period of delayed demixing oc-
curred, and similar to what was observed with implants con-
taining DiI, the polymer-lean domains aggregated resulting in
the observed increase in size and decrease in interconnectivity
of the porous network between days 3 and 7 (Figs. 6 and 7). The
subsequent changes in microstructure most likely resulted in a
decrease in the dissolution of drug during the diffusion period
of release.
CONCLUSIONS
Medical imaging systems provide a powerful tool by which the
long-term in situ behavior of implants can be evaluated nonde-
structively and aid in the rational design of implant formula-
tions. Excipients provide an ideal method by which the release
profile can be tailored for specific applications. The findings in
this study have demonstrated that excipients can be used to
reduce burst release, alter diffusivity, as well as delay the on-
set of degradation-facilitated release. Understanding how the
additives alter microstructure and interact with the matrix can
be used to tailor the release profile of ISFIs for specific applica-
tions. It has been demonstrated that changes in the microstruc-
ture can significantly alter the release profile.14,22,23,44 Cur-
rently, only a handful of additives have been evaluated,30,31,45
with a large focus of research evaluating the role of solvents
and the polymer.21,24,25,29,46–51 These findings demonstrate that
the use of additives can significantly alter the implant release
profile, within the different periods of release.
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